Related Experiment Video
Updated: May 12, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Mechanotransduction in cancer stem cells
Jin Hao1, Yueling Zhang, Rui Ye
1Department of Orthodontics, State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China.
Cell Biology International
|April 12, 2013
Summary
Cancer stem cells (CSCs) drive tumor growth and resistance. Targeting mechanotransduction, a pathway involving FAK/PI3K/Akt, offers a novel therapeutic strategy against CSCs for improved cancer treatment outcomes.
Area of Science:
- Oncology
- Cell Biology
- Biophysics
Background:
- The cancer stem cell (CSC) hypothesis posits that a subpopulation of malignant cells sustains tumor growth, metastasis, and treatment resistance.
- Understanding CSC biology is crucial for developing effective cancer therapies.
- Recent research emphasizes the role of extracellular matrix physical properties and mechanotransduction in cancer development.
Purpose of the Study:
- To explore mechanotransduction as a potential therapeutic target for cancer stem cells (CSCs).
- To investigate the role of CXCR1 and the FAK/PI3K/Akt pathway in CSCs.
- To propose innovative cancer treatment strategies by inhibiting key mechanotransduction mediators.
Main Methods:
- Review of recent advancements in cancer stem cell research.
- Analysis of signaling pathways involved in mechanotransduction.
- Identification of upstream regulators like CXCR1 and downstream effectors such as FAK/PI3K/Akt.
Main Results:
- CSCs are critical drivers of tumor progression, metastasis, and therapeutic resistance.
- The FAK/PI3K/Akt pathway is a key mediator in mechanotransduction within cancer cells.
- CXCR1 has been identified as an upstream signaling molecule influencing this pathway in CSCs.
Conclusions:
- Mechanotransduction represents a promising novel target for therapeutic intervention in cancer stem cells.
- Inhibiting the FAK/PI3K/Akt pathway offers an innovative approach to combatting CSC-driven cancers.
- Targeting mechanotransduction pathways could significantly improve patient outcomes in cancer treatment.
Related Concept Videos
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...